Cytokinetics CYTK Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -605.1%+90.4pp | -695.4%-38.5pp | -656.9%-19.0pp | -638%+2,305pp | -2,943.3%-40.6pp | |
| Net margin | -784%+108pp | -891.6%-29.4pp | -862.2%-155pp | -707.2%+2,494pp | -3,201.5%-10.4pp | |
| EBITDA margin | -594.5%+89.5pp | -683.9%-38.1pp | -645.9%-18.9pp | -627%+2,267pp | -2,893.9%-42.7pp | |
| Free cash flow margin | -518.8%+88.7pp | -607.5%-87.6pp | -519.9%-8.2pp | -511.7%+1,609pp | -2,120.8%+43.3pp | |
| Returns | ||||||
| Return on assets | -65.4%-9.8pp | -55.5%-3.2pp | -52.4%-8.2pp | -44.1%+15.3pp | -59.4%-6.4pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 4.2×-0.3× | 4.5×-2.3× | 6.9×+0.1× | 6.8×+0.8× | 6×-0.2× | |
| Quick ratio | 4.2×-0.3× | 4.5×-2.3× | 6.9×+0.1× | 6.8×+0.8× | 6×-0.2× | |
| Cash ratio | 0.7×0.0× | 0.6×-1.0× | 1.6×+1.0× | 0.6×+0.1× | 0.5×-0.1× | |
| Leverage | ||||||
| Debt-to-assets | 0.3×0.0× | 0.3×+0.1× | 0.2×0.0× | 0.2×+0.1× | 0.2×0.0× | |
| Interest coverage | -12.5×+0.9× | -13.4×+0.8× | -14.2×+0.2× | -14.5×-0.1× | -14.3×-0.1× | |
| Per Share | ||||||
| Book value per share | -$6.71-22.1% | -$5.49-26.5% | -$4.34-40.7% | -$3.09-37.3% | -$2.25-86.0% | |
| Valuation | ||||||
| Market capitalization | $8.12B+4.5% | $7.77B+18.1% | $6.58B+64.9% | $3.99B-16.2% | $4.76B-14.3% | |
| Enterprise value | $8.41B+4.3% | $8.06B+21.1% | $6.66B+57.9% | $4.22B-14.3% | $4.92B-13.5% | |
| Price / sales | 76.7×-11.5× | 88.2×+12.8× | 75.4×+28.9× | 46.5×-201× | 247.6×-52.9× | |
| EV / sales | 79.4×-12.1× | 91.6×+15.2× | 76.3×+27.1× | 49.2×-207× | 256.2×-52.0× | |
| Free cash flow yield | -6.8%+0.1pp | -6.9%0.0pp | -6.9%+4.1pp | -11%-2.4pp | -8.6%-1.4pp | |
| Earnings yield | -10.2%-0.1pp | -10.1%+1.3pp | -11.4%+3.8pp | -15.2%-2.3pp | -12.9%-2.3pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Cytokinetics's ratios come from?
- Every ratio is computed from Cytokinetics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
